Therefore, we focused on apatinib, which has been shown to yield significant therapeutic benefit and is the first anti‐angiogenic agent approved by the cFDA for the treatment of refractory GC.[5, 6] As an inhibitor of angiogenesis, apatinib exacerbates hypoxia in tumor tissue and results in an overdependence on glycolysis of tumor cells to cope with increased metabolic and survival stress.[9, 10] It is consistent with our findings that a NAT10/SEPT9/HIF‐1α positive feedback loop regulates glycolysis addiction. This evidence concerns the gene SEPTIN9 and neoplasm.